DAXOR CORP (10-Q) Summary: Quarter Ended March 31, 2007
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended March 31, 2007. DAXOR Corporation operates as a medical device manufacturer focusing on the Blood Volume Analyzer (BVA-100) and related diagnostic kits, alongside a cryobanking subsidiary (Scientific Medical Systems Corp.) providing blood and semen storage. The company maintains a significant investment portfolio, primarily in utility stocks, which serves as a critical source of income to offset operating losses.
Key Financial Metrics
| Metric | Q1 2007 | Q1 2006 |
|---|---|---|
| Operating Revenue | $505,882 | $342,146 |
| Gross Profit | $354,347 | $224,218 |
| Operating Loss | $(1,205,867) | $(1,272,119) |
| Investment Income (Net) | $4,340,519 | $1,327,450 |
| Net Income | $3,059,994 | $(38,982) |
| Cash and Equivalents (End of Period) | $78,625 | $37,818 |
| Total Assets | $83,468,271 | $58,936,708 |
| Stockholders' Equity | $51,343,092 | $45,637,792 |
Debt and Liquidity: Current liabilities totaled $31.7 million, heavily influenced by a $16.8 million deferred tax liability related to unrealized investment gains. Short-term loans payable were $3.5 million. The company holds $71.2 million in available-for-sale securities.
Material Changes vs. Prior Period
- Revenue Growth: Operating revenue increased 47.9% to $505,882, driven by the sale of two BVA-100 units ($130,500) and a 20.9% increase in kit sales due to a larger installed base (53 units vs. 34 units) and a 5% price increase.
- Profitability Shift: The company swung from a net loss of $39,000 in Q1 2006 to a net income of $3.06 million in Q1 2007. This turnaround is almost entirely attributable to investment income, which rose from $1.33 million to $4.34 million.
- Investment Performance: Net investment income surged due to a $1.63 million gain on the sale of securities and a $2.01 million mark-to-market gain on short positions and options, compared to $74,587 in the prior year.
- Operating Expenses: Total operating expenses increased slightly to $1.56 million. R&D expenses rose to $751,815 (from $557,508) to support new product development (GFR testing, Max-200 delivery device).
- Cash Flow: Net cash used in operating activities was $829,015. Investing activities provided $1.78 million, while financing activities used $3.71 million, primarily due to net repayments on margin loans.
Outlook, Risks, and Contingencies
- Management Commentary: Management intends to expand the sales force and regional managers to support the BVA-100. They are also developing renal function testing instrumentation. The investment portfolio remains a critical buffer against operating losses.
- SEC Investigation: The SEC has recommended bringing an action against the Company and its CEO, Dr. Joseph Feldschuh, for alleged violations of Section 7(a) of the Investment Company Act. The Company asserts it is an operating company, not an investment company, and has agreed to indemnify the CEO for related expenses.
- Concentration Risk: Four hospital customers accounted for 47.67% of total consolidated sales. The loss of any single customer could have an adverse short-term effect.
- Supply Chain Risk: Volumex syringes are filled by a single FDA-approved manufacturer. Discontinuation by this supplier would materially impact the business.
- Market Risk: The portfolio is heavily concentrated in electric utilities. While unrealized gains are substantial ($48 million), the portfolio is exposed to interest rate fluctuations and regulatory changes affecting utilities.
Investor Verification Checklist
- Investment vs. Operations: Verify the sustainability of the $4.3 million investment income, which masked a $1.2 million operating loss. Determine if this income is recurring or driven by one-time mark-to-market adjustments.
- SEC Status: Monitor the outcome of the SEC recommendation regarding the Investment Company Act violation, as this could fundamentally alter the company's regulatory status and operations.
- Cash Position: Note the low cash balance ($78,625) despite high asset values. Assess liquidity risks given the heavy reliance on margin loans and the potential tax liability if the investment portfolio is liquidated.
- Customer Concentration: Evaluate the stability of the four major hospital customers representing nearly half of operating revenue.
- Deferred Tax Liability: Understand that the $16.8 million deferred tax liability is contingent on the sale of the investment portfolio; it is not a cash obligation unless assets are sold.